# Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide

> **NCT02169466** · PHASE1 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 22 (actual)

## Conditions studied

- Parkinson's Disease (PD)

## Interventions

- **DRUG:** BIA 9-1067
- **DRUG:** Placebo
- **DRUG:** Madopar® HBS

## Key facts

- **NCT ID:** NCT02169466
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2015-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02169466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02169466, "Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02169466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*